Share on whatsapp
Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) went down by -1.98% from its latest closing price compared to the recent 1-year high of $142.20. The company’s stock price has collected -1.60% of loss in the last five trading sessions. Barron’s reported on 04/23/21 that How Soon Before the Chip Shortage Ends? Taiwan Semi Looks to 2022.
Is It Worth Investing in Taiwan Semiconductor Manufacturing Company Limited (NYSE :TSM) Right Now?
Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) scored a price-to-earnings ratio above its average ratio, recording 31.20 x from its present earnings ratio. Plus, the 36-month beta value for TSM is at 0.90. Opinions of the stock are interesting as 25 analysts out of 34 who provided ratings for Taiwan Semiconductor Manufacturing Company Limited declared the stock was a “buy,” while 6 rated the stock as “overweight,” 2 rated it as “hold,” and 1 as “sell.”
Author Bio
Rhian Hunt grew up in a crowded Connecticut suburb before moving to Wisconsin, where he enjoys being an outdoorsman, relishing the struggle against mountainous snowfalls during the eternal-seeming winters and aerial armadas of mosquitoes over the summer. Rhian studied Business Economics and Microeconomics at the University of Wisconsin. A lifelong interest in writing led to first professional freelancing, then becoming a Motley Fool author.
With a home improvement boom triggered by government COVID-19 lockdown orders under way since 2020,
Lowe s (NYSE:LOW) is planning a spring hiring fair next week at which it expects to add 50,000 employees to its payroll. Though many will be temporary, seasonal workers, the new hires are still potentially a barometer of Lowe s ongoing growth, considering they come on top of 90,000 more new employees added over the course of the past 12 months, according to today s press release.
Amgen (AMGN)
In a report released yesterday, Brian Skorney from Robert W. Baird reiterated a Sell rating on Amgen, with a price target of $185.00. The company’s shares closed last Wednesday at $236.71.
According to TipRanks.com, Skorney is a 4-star analyst with an average return of 5.8% and a 51.1% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Intellia Therapeutics.
Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $250.24, which is a 3.6% upside from current levels. In a report released yesterday, Atlantic Equities also downgraded the stock to Sell with a $200.00 price target.